Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S. doi: 10.1097/00004583-200202001-00003.

Abstract

This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed-salts amphetamine, and pemoline. It carries FDA indications for treatment of attention-deficit/hyperactivity disorder and narcolepsy.

Publication types

  • Guideline
  • Practice Guideline
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Amphetamines / therapeutic use
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Brain / drug effects*
  • Central Nervous System Stimulants / adverse effects
  • Central Nervous System Stimulants / pharmacology
  • Central Nervous System Stimulants / therapeutic use*
  • Child
  • Child, Preschool
  • Contraindications
  • Drug Monitoring
  • Evidence-Based Medicine
  • Humans
  • Methylphenidate / therapeutic use
  • Narcolepsy / drug therapy
  • Pemoline / therapeutic use
  • Psychopharmacology
  • Psychotropic Drugs / therapeutic use*
  • United States

Substances

  • Amphetamines
  • Central Nervous System Stimulants
  • Psychotropic Drugs
  • Methylphenidate
  • Pemoline